争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 7 条
2026
法国在出现死亡关联后召回Tavneos批次
宣布召回
法国药品安全机构ANSM表示,法国境内所有Tavneos批次将于8月19日开始召回。该药由美国生物技术公司安进生产,并由全球不同合作伙伴药企销售,此前在日本被指与20例死亡相关。欧盟委员会本月早些时候已撤销该药的上市许可。
品牌回应
召回 — France's medicine safety agency ANSM
"The recall of all batches available in France will begin on August 19," France's medicine safety agency ANSM said in a statement.
来源摘录
The European Commission revoked the drug's marketing authorisation earlier this month because "the benefits are no longer proven to outweigh its risks".
Kissei Pharmaceutical, which sells the drug in Japan, said in May that 20 deaths had been reported among people using the it since 2022.
A drug called Tavneos used to treat rare autoimmune diseases will be pulled from the shelves in France, the country's medicine watchdog said Wednesday, after it was linked to 20 deaths in Japan.
2024
安进就药品定价委员会起诉科罗拉多州
提起诉讼
安进就科罗拉多州处方药可负担性委员会对Enbrel采取的行动起诉该州。据报道,安进称委员会的行动违宪,并要求推翻有关该药的决定及废除设立该委员会法律的部分内容。
品牌回应
澄清 — Amgen
“We have significant concerns with the Colorado Prescription Drug Affordability Board’s decision to move forward with its flawed policy and process,” Amgen said in a statement. “There is no legal basis for the Board’s actions or haphazard process throughout the review period.”
来源摘录
In a lawsuit filed Friday in U.S. District Court in Denver, Amgen argues that the actions of Colorado’s Prescription Drug Affordability Board are unconstitutional because they conflict with federal laws and because they violate rights to due process.
The company is seeking not just to overturn the board’s recent decisions about Enbrel but also to strike down major parts of the law creating the board.
Amgen says the law also potentially interferes with Medicare’s ability to control its pricing decisions.
2024
山德士与安进就美国地舒单抗专利争议达成和解
和解
山德士宣布与安进达成协议,解决涉及山德士已获FDA批准的地舒单抗生物类似药的专利争议。根据协议,山德士可于2025年5月31日或符合特定条件时更早进入美国市场,销售Prolia和Xgeva的生物类似药。
来源摘录
Under the terms of the agreement, Sandoz may enter the US market with a biosimilar version of Prolia® and Xgeva® on May 31, 2025, or earlier under certain circumstances if customary acceleration provisions are triggered.
Patent infringement proceedings were initially filed by Amgen in the US Federal District Court for the District of New Jersey in May of 2023 pursuant to the Biologics Price Competition and Innovation Act (BPCIA).
Basel, April 30, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that it has reached agreement with Amgen to resolve all patent disputes between the two companies relating to the US Food and Drug Administration (FDA)-approved Sandoz denosumab biosimilars.
2023
美国联邦贸易委员会起诉阻止安进收购Horizon Therapeutics
提起诉讼
美国联邦贸易委员会提起诉讼,要求阻止安进拟以278亿美元收购Horizon Therapeutics。FTC称担心安进会利用其畅销药物向保险公司和药品福利管理机构施压,要求其为Horizon产品提供有利条款。安进表示失望,并否认该交易存在实质性竞争问题。
品牌回应
否认 — Amgen
Amgen said in a statement it was disappointed by the FTC decision and that it believed it had "overwhelmingly demonstrated" that the deal had no legitimate competitive issues.
来源摘录
The US Federal Trade Commission has said it will sue to stop Amgen's $27.8 billion acquisition of Horizon Therapeutics in a rare move to block a large pharmaceutical deal.
In its complaint, the FTC said Amgen would be able to use the powerful position it has with insurance companies and pharmacy benefit managers due to its blockbuster drugs to pressure them into favorable terms for Horizon's two key products - the fast-growing thyroid eye disease treatment Tepezza and gout drug Krystexxa.
Amgen said in a statement it was disappointed by the FTC decision and that it believed it had "overwhelmingly demonstrated" that the deal had no legitimate competitive issues.
2023
安进就拟议生物类似药起诉诺华和山德士
提起诉讼
安进在新泽西州联邦法院起诉诺华及其山德士业务,指控山德士拟推出的Prolia和Xgeva生物类似药侵犯专利,并请求法院在专利到期前禁止这些产品。该争议涉及拟议的生物类似药产品以及Prolia和Xgeva的专利保护。
Amgen在新泽西州联邦法院起诉Novartis及其Sandoz业务,指控Sandoz拟推出的Prolia和Xgeva生物类似药侵犯专利,并请求法院在专利到期前禁止这些产品。
来源摘录
Amgen asked the court to block Sandoz's biosimilars of the drugs until its patents expire.
Amgen Inc sued Novartis AG's Sandoz in New Jersey federal court Monday, accusing Sandoz's proposed versions of its multibillion-dollar bone-strengthening drugs Prolia and Xgeva of infringing several patents.
The plaintiffs are seeking a declaration that Amgen infringed upon the ‘421, ‘158 and ‘149 patents, actual damages, interest, attorney’s fees and costs, and other relief.
2021
安进在专利争议中向美国最高法院提交请愿书
提起诉讼
Amgen Inc.及其子公司向美国最高法院提交调卷令请愿书,所涉对方为Sanofi Aventisub LLC、Regeneron Pharmaceuticals Inc.和Sanofi-Aventis US, LLC。请愿书涉及专利书面描述要求及其所需的详细程度。
来源摘录
On Monday a petition for certiorari was filed to the Supreme Court of the United States by Amgen Inc. and its subsidiaries against Sanofi Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis US, LLC.
2012